# US 2020/0390740 A1 · Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390740 A1
- Document ID: US20200390740A1
- Status: Published application
- Kind: A1
- Application number: 16/303,249
- Filed: 2017-05-19
- Published: 2020-12-17
- Earliest claimed: 2016-05-20
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite De Lille; Institut Pasteur de Lille; Centre National de la Recherche Scientifique (CNRS)
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Universite De Lille; Institut Pasteur De Lille; Centre National De La Recherche Scientifique - Cnrs -
- Inventors: Mathias CHAMAILLARD
- Web page: https://patentgrep.com/patent/US20200390740A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/20: Hypnotics; Sedatives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

## Claims

### Claim 1

A method for treating microbiome dysregulations associated with circadian clock disruption in a subject in need thereof, said method comprising a step of administering an inhibitor of the casein kinase 2 (Csnk2) activity.

### Claim 2 (depends on 1)

The method according to claim 1, wherein microbiome dysregulation includes dysbiosis and/or loss of diurnal rhythmicity of the gut microbiota.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the subject suffers from or is at risk of a circadian rhythm sleep disorder.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the inhibitor of the casein kinase 2 (Csnk2) activity is selected among flavones, tyrphostins and their derivatives.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the inhibitor of the casein kinase 2 (Csnk2) activity is selected from the group consisting in apigenin, luteolin, and tyrphostin AG99.
